Bright Minds Biosciences Inc.
DRUG
Rank in Stocks
#12399
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Share Price
$56.48
Last synced: 2026-10-20
Market Cap
$557.12M
Change (1 day)
4.94%
Change (1 year)
-16.20%
Country
US
Trade Bright Minds Biosciences Inc. (DRUG)
Category
Healthcare
P/B ratio for Bright Minds Biosciences Inc. (DRUG)
P/B ratio as of 2026 TTM: 0
According to Bright Minds Biosciences Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Bright Minds Biosciences Inc. from 2026 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
